Tissue microarray-based immunohistochemical study can significantly underestimate the expression of HER2 and progesterone receptor in ductal carcinoma in situ of the breast

Biotechnic and Histochemistry

Volumn 86, Issue 5, 2011, Pages 345-350

  Lin, Y ^a   Hatem, J ^a   Wang, J ^b   Quinn, A ^a   Hicks, D G ^a   Tang, P ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

Author keywords

ductal carcinoma in situ; estrogen receptor; HER2; immunohistochemistry; progesterone receptor; tissue microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST TUMOR; CHEMISTRY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; METABOLISM; METHODOLOGY; PATHOLOGY; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS;

EID: 80052575513     PISSN: 10520295     EISSN: 14737760     Source Type: Journal    
DOI: 10.3109/10520295.2010.502845     Document Type: Article

References (28)

1. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JFR, Macmillan D, Blamey RW, Ellis IO (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterized series identifi es biologically distinct classes of breast cancer confi rming recent cDNA expression analyses. Int. J. Cancer 116: 340-350. (Pubitemid 40993329)
2. Bubendorf L, Nocito A, Moch H, Sauter G (2001) Tissue microarray (TMA) technology miniaturized pathology archives for high-throughput in situ studies. J. Pathol. 195: 72-79.
3. Callagy G, Cattaneo E, Daigo Y, Happerfi eld L, Bobrow LG, Pharoah PD, Caldas C (2003) Molecular classifi cation of breast carcinomas using tissue microarrays. Diagn. Mol. Pathol. 12: 27-34. (Pubitemid 36255267)
4. Camp RL, Charette LA, Rimm DL (2000). Validation of tissue microarray technology in breast carcinoma. Lab. Invest. 80: 1943-1949. (Pubitemid 32012762)
5. Chhieng DC, Frost AR, Niwas S, Weiss H, Grizzle WE, Beeken S (2004) Intratumor heterogeneity of biomarker expression in breast carcinomas. Biotech. & Histochem. 79: 25-36. (Pubitemid 38997102)
6. Cohen, J. (1960) A coeffi cient of agreement for nominal scales. Ed. Psychol. Meas. 20: 37-46.
7. Collins LC, Schnitt SJ (2005) HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy. Mod. Pathol. 18: 615-620. (Pubitemid 40676371)
8. Denk H (1988) Immunohistologic heterogeneity of malignant tumors. Pathol. Res. Pract. 183: 693-697.
9. Graham AD, Faratian D, Rae F, Thomas J St J (2008) Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: A prospective study of the use of immunohistochemistry and fl uorescence in situ hybridization. Histopathology 52: 847-855. (Pubitemid 351724917)
10. Hoos A, Cordon-Cardo C (2001) Tissue microarray profi ling of cancer specimens and cell lines: Opportunities and limitations. Lab. Invest 81: 1331-1338. (Pubitemid 32980155)
11. Horvath L, Henshall S (2001) The application of tissue microarrays to cancer research. Pathology 33:125-129. (Pubitemid 32453402)
12. Kallioniemi OP, Wagner U, Kononen J, Sauter G (2001) Tissue microarray technology for high-throughput molecular profi ling of cancer. Hum. Mol. Genet 10: 657-662. (Pubitemid 32331572)
13. Khoury T, Sait S, Hwang H, Chandrasekhar R, Wilding G, Tan D, Kulkarni S (2009) Delay to formalin fi xation effect on breast biomarkers. Mod. Pathol. 22: 1457-1467.
14. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniem OP (1998) Tissue microarrays for high throughput molecular profi ling of tumor specimens. Nat. Med 4: 844-847. (Pubitemid 28331029)
15. Lewis JT, Ketterling RP, Halling KC, Reynolds C, Jenkins RB, Visscher DW (2005) Analysis of intratumoral heterogeneity and amplifi cation status in breast carcinomas with equivocal (2+ ) HER-2 immunostaining. Am. J. Clin. Pathol. 124: 273-281. (Pubitemid 41060140)
16. Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG (2007) Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod. Pathol 20: 84-89. (Pubitemid 44967953)
17. McNemar Q (1947) Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika 12: 153-157.
18. Merseburger AS, Kuczyk MA, Serth J, Bokemeyer C, Young DY, Sun L, Connelly RR, Mcleod DG, Mostofi FK, Srivastava SK, Stenzl A, Moul JW, Sesterhenn IA (2003) Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. Oncol. Rep 10: 223-228.
19. Park K, Han S, Shin E, Kim HJ, Kim JY (2006) Cox-2 expression on tissue microarray of breast cancer. Eur. J. Surg. Oncol. 32: 1093-1096. (Pubitemid 44774393)
20. Quinn AM, Tang P, Yang Q, Bourne PA (2008) Tissue array construction: Pitfalls, problems, and progress. Appl. Immunohistochem Mol. Morphol. 16: 287-290. (Pubitemid 351589553)
21. Schmidt LH, Biesterfeld S, Kummel A, Faldum A, Sebastian M, Taube C, Buhl R, Wiewrodt R (2009) Tissue microarrays are reliable tools for clinicopathological characterization of lung cancer tissue. Anticancer Res. 29: 201-209.
22. Siitonen SM, Isola JJ, Rantala IS, Helin HJ (1993) Intratumor variation in cell proliferation in breast carcinoma as determined by antiproliferating cell nuclear antigen monoclonal antibody and automated image analysis. Am. J. Clin. Pathol. 99: 224-231.
23. Simon R, Sauter G (2002) Tissue microarrays for miniaturized high-throughput molecular profi ling of tumors. Exp. Hematol. 30:1365-1372. (Pubitemid 35449792)
24. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98: 10869-10874. (Pubitemid 32878711)
25. Szollosi J, Balazs M, Feuerstein BG, Benz CC, Waldman FM (1995) ERBB-2 (HER2/neu) gene copy number, p185 HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res. 55: 5400-5407.
26. Tovey S, Dunne B, Witton C, Forsyth A, Cooke TG (2005) Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin. Cancer Res. 11: 4835-4842. (Pubitemid 41557203)
27. van de Rijn M, Perou CM, Tibshirani R, Haas P. Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Kochli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D, Brown P (2002) Expression of cytokeratin 17 and 5 identifi es a group of breast carcinomas with poor clinical outcome. Am. J. Pathol 161: 1991-1996. (Pubitemid 35434844)
28. van der Vegt B, de Bock GH, Hollema H, Wesseling J (2009) Microarray methods to identify factors determining breast cancer progression: Potentials, limitations, and challenges. Crit. Rev. Oncol 70: 1-11.